Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
181 hedge funds and large institutions have $3.05B invested in Intercept Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 81 increasing their positions, 47 reducing their positions, and 21 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
72% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 47
8% more funds holding
Funds holding: 167 → 181 (+14)
2% less capital invested
Capital invested by funds: $3.12B → $3.05B (-$62.2M)
39% less call options, than puts
Call options by funds: $109M | Put options by funds: $179M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carmignac Gestion
Paris,
France
|
+$84.1M |
| 2 |
Millennium Management
New York
|
+$74.9M |
| 3 |
CCI
Columbus Circle Investors
|
+$39.2M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$38.3M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$298M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$91.6M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$49.2M |
| 4 |
O
OrbiMed
New York
|
-$43.7M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$31.4M |
ICPT Hedge Fund Activity: Q3 2014 in Review
181 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q3 2014, worth a combined $3.05B — down 2% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ICPT positions and 21 closed out — a net gain of 16 holders — while 81 added to existing stakes and 47 trimmed.
The largest buyer was Carmignac Gestion, adding an estimated $84.1M. The largest seller was Jennison Associates, cutting an estimated $298M.
- 181 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q3 2014, up from 167 in Q2 2014.
- Funds reported $3.05B of Intercept Pharmaceuticals, Inc. stock for Q3 2014, down 2% quarter-over-quarter.
- 37 funds opened new Intercept Pharmaceuticals, Inc. positions in Q3 2014 and 21 closed out, a net change of +16 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q3 2014 was Carmignac Gestion, an estimated $84.1M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q3 2014 was Jennison Associates, an estimated $298M sold.
Based on aggregated 13F filings for Q3 2014.